Florian Härtig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Florian Härtig has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Grimm
Department of Epileptology, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
1 shared publication - Andreas Peter
Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, Tübingen, Germany
1 shared publication - Charlotte Spencer
Department of Neurology & Stroke, and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
1 shared publication - Christine Stephanie Zuern
Division of Cardiology, Department of Medicine (P.B.M., S.A., S.O., F.M., C.S.Z., M.K.), University Hospital Basel, Switzerland
1 shared publication - Eva Auffenberg
Center for Neurology, Tübingen University Hospital and Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen, Tübingen, Germany
1 shared publication - Gunnar Blumenstock
Institute for Clinical Epidemiology and Applied Biometry (Head: Prof. Dr. rer. nat. P. Martus), University Hospital Tuebingen, Silcherstrasse 5, Tuebingen, 72076, Germany
1 shared publication
Latest Publications
- 1 December 2017
- Published by Elsevier in Clinical Neurophysiology
- Vol. 128 (12) , 2521-2526
A look inside the nerve – Morphology of nerve fascicles in healthy controls and patients with polyneuropathy
- 1 December 2017
- Published by Elsevier in Clinical Neurophysiology
- Vol. 128 (12) , 2521-2526
A look inside the nerve – Morphology of nerve fascicles in healthy controls and patients with polyneuropathy
- Open Access
- 15 February 2017
- Published by Springer Nature in Critical Care
- Vol. 21 (1) , 1-9
Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants
Point-of-care testing (POCT) of coagulation has been proven to be of great value in accelerating emergency treatment. Specific POCT for direct oral anticoagulants (DOAC) is not available, but the effects of DOAC on established POCT have been described. We aimed to determine the diagnostic accuracy of Hemochron® Signature coagulation POCT to qualitatively rule out relevant concentrations of apixaban, rivaroxaban, and dabigatran in real-life patients. We enrolled 68 patients receiving apixaban, rivaroxaban, or dabigatran and obtained blood samples at six pre-specified time points. Coagulation testing was performed using prothrombin time/international normalized ratio (PT/INR), activated partial thromboplastin time (aPTT), and activated clotting time (ACT+ and ACT-low range) POCT cards. For comparison, laboratory-based assays of diluted thrombin time (Hemoclot) and anti-Xa activity were conducted. DOAC concentrations were determined by liquid chromatography-tandem mass spectrometry. Four hundred and three samples were collected. POCT results of PT/INR and ACT+ correlated with both rivaroxaban and dabigatran concentrations. Insufficient correlation was found for apixaban. Rivaroxaban concentrations at <30 and 95% specificity at PT/INR POCT ≤1.0 and ≤1.1 and ACT+ POCT ≤120 and ≤130 s. Dabigatran concentrations at <30 and 95% specificity at PT/INR POCT ≤1.1 and ≤1.2 and ACT+ POCT ≤100 s. Hemochron® Signature POCT can be a fast and reliable alternative for guiding emergency treatment during rivaroxaban and dabigatran therapy. It allows the rapid identification of a relevant fraction of patients that can be treated immediately without the need to await the results of much slower laboratory-based coagulation tests. Unique identifier, NCT02371070 . Retrospectively registered on 18 February 2015.
- 15 February 2017
- Published by Springer Nature in Critical Care
- Vol. 21 (1) , 1-9
Open AccessPoint-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants
Point-of-care testing (POCT) of coagulation has been proven to be of great value in accelerating emergency treatment. Specific POCT for direct oral anticoagulants (DOAC) is not available, but the effects of DOAC on established POCT have been described. We aimed to determine the diagnostic accuracy of Hemochron® Signature coagulation POCT to qualitatively rule out relevant concentrations of apixaban, rivaroxaban, and dabigatran in real-life patients. We enrolled 68 patients receiving apixaban, rivaroxaban, or dabigatran and obtained blood samples at six pre-specified time points. Coagulation testing was performed using prothrombin time/international normalized ratio (PT/INR), activated partial thromboplastin time (aPTT), and activated clotting time (ACT+ and ACT-low range) POCT cards. For comparison, laboratory-based assays of diluted thrombin time (Hemoclot) and anti-Xa activity were conducted. DOAC concentrations were determined by liquid chromatography-tandem mass spectrometry. Four hundred and three samples were collected. POCT results of PT/INR and ACT+ correlated with both rivaroxaban and dabigatran concentrations. Insufficient correlation was found for apixaban. Rivaroxaban concentrations at <30 and 95% specificity at PT/INR POCT ≤1.0 and ≤1.1 and ACT+ POCT ≤120 and ≤130 s. Dabigatran concentrations at <30 and 95% specificity at PT/INR POCT ≤1.1 and ≤1.2 and ACT+ POCT ≤100 s. Hemochron® Signature POCT can be a fast and reliable alternative for guiding emergency treatment during rivaroxaban and dabigatran therapy. It allows the rapid identification of a relevant fraction of patients that can be treated immediately without the need to await the results of much slower laboratory-based coagulation tests. Unique identifier, NCT02371070 . Retrospectively registered on 18 February 2015.